Science

The newsroom coffee tastes like burnt rubber and broken promises. My phone keeps buzzing with the same kind of alert that only hits when power gets caught with its hand in the grant drawer: the government blinked. Not with a press conference. Not with an apology. With a deadline that came and went, quietly, like a lobbyist slipping out of a hearing before the questions start landing.

This week, the Trump administration let the window close to ask the US Supreme Court to revive the NIH’s flat 15% cap on reimbursing universities and medical centers for so-called indirect costs of research. The cap is dead, at least in this lawsuit. And no, the people who tried to impose it are not suddenly going to respect public science. They are just going to look for a new host body.

What happened: the Supreme Court deadline passed

On February 7, 2025, NIH announced it would cap reimbursements for indirect costs at 15%, replacing negotiated rates that commonly run higher. The policy got sued immediately. A federal appeals court later upheld a permanent block, finding NIH’s move unlawful, including because of a long-running appropriations rider and because NIH ran roughshod over HHS regulations that require negotiated rates to be accepted absent a proper deviation process. Then the administration simply did not file a Supreme Court petition before the deadline. Door closed.

Translation: “indirect costs” are the lights, the locks, and the people

Translation: “Indirect costs” is the phrase that lets politicians cosplay as accountants while they set fire to the infrastructure that makes research possible.

These dollars pay for electricity that keeps freezers from thawing. Compliance staff that protects human subjects. Techs who keep instruments calibrated. Cybersecurity that keeps patient data from being sold like loose cigarettes. Calling it “overhead” is like calling brakes “optional accessories.”

And the government’s own brag sheet tells you the size of the cut. The First Circuit opinion notes NIH publicly touted more than $4 billion a year in “savings” from the cap. That is not trimming fat. That is a planned amputation.

Here is the mechanism: sabotage the commons, then sell the cure

Here is the mechanism: you kneecap the public pipeline, then point at the wobbling and call it “inefficient.” Then you invite private capital to “modernize” what you just damaged on purpose.

If you cap indirects, you do not just hurt Harvard. You hit state university medical centers, regional cancer centers running trials, and public health labs that sequence outbreaks. You squeeze graduate students and postdocs who already keep the engine running while being paid like a rounding error.

Follow the money: costs shift down, control shifts up

Follow the money: the cap would have shifted costs off the federal ledger and onto institutions, workers, students, and patients. That turns federally funded science into an unfunded mandate. When budgets blow up, you get hiring freezes, delayed maintenance, and soft privatization.

And the retreat now? No “we were wrong.” Just silence. C&EN reports the White House and DOJ did not respond to requests for comment. Silence is a strategy when you want the heat to die down but the agenda to survive.

The quiet part: it was also a loyalty test

The quiet part: when funding can be yanked by administrative fiat, institutions start self-censoring. They pick “safer” topics. They learn the new rules without anyone writing them down.

Today, the cap is blocked. Good. Take the win like a receipt, not a bedtime story. Demand oversight, audits, and hearings where officials explain who drafted the cap, who lobbied for it, and what pressure got applied. Because if they cannot kill research by cap, they will try it by conditions, gag rules, and budget starvation.

I read court dockets the way you read a fire code: not for fun, but because you prefer buildings that stay standing. This week’s plot twist is quiet but decisive. The Trump administration let the deadline pass to ask the U.S. Supreme Court to revive an NIH policy that would have capped reimbursement for research “indirect costs” at 15%. No filing, no comeback. This particular cap is done.

What happened, in plain English

• February 2025: NIH issued a short notice announcing a 15% cap on indirect-cost reimbursement, effective the next business day.
• Lawsuits arrived immediately. A federal judge blocked the policy.
• January 2026: The First Circuit affirmed, leaving the cap dead unless the Supreme Court took it up.
• This week, DOJ let the Supreme Court deadline pass. The legal effort ends by default.

Universities and research hospitals can exhale. For now. But civics is never “problem solved.” It is “watch the next door,” because power that fails through the front entrance tends to try the air vents.

The Orwell check: “overhead” is doing political work

Call it “overhead” and people picture mahogany desks and catered seminars on “synergy.” Call it what it is, facilities and administrative costs, and you’re talking animal care, chemical waste disposal, patient privacy rules, cybersecurity, freezer alarms, and the compliance staff who keep trials legal and labs lit.

The rhetorical trick is that “indirect” sounds optional. But modern biomedical research is a regulated enterprise. Grants operate under federal rules with non-optional requirements, and the First Circuit opinion describes NIH’s longstanding architecture: documented direct costs plus documented indirect costs under a regulatory framework. The agency tried to rewrite that architecture through guidance, quickly.

The tradeoff: auditing versus the blunt instrument

I am not allergic to scrutiny. If someone pads expenses, investigate, negotiate harder, claw back improper charges, prosecute fraud if it is fraud. That is a scalpel.

An across-the-board cap imposed at speed is a meat cleaver. It ignores real differences among institutions, including costly compliance and safety operations, and treats physical realities like rent, utilities, and regulated-science infrastructure as if they were moral failings.

The liberty ledger: leverage, not just budgets

If NIH can unilaterally shrink the reimbursement that makes research hostable, the agency and the White House gain quiet leverage: you do not have to ban a field if you can make it financially impossible to run. The public, patients, and researchers lose stability, and researchers lose a smaller freedom too: pursuing questions without needing to flatter the current administration to keep the lights on.

The Paine test: restraint today, pressure tomorrow

Letting the Supreme Court deadline pass is restraint in one narrow sense. Good. But reporting and policy signals suggest the administration may try to reshape indirect-cost policy through government-wide grant rules rather than that NIH notice.

Courts did their job here. Now Congress should insist that any future changes happen in sunlight, through proper processes, with the guardrails NIH itself cites for FY2026. Otherwise we get governance by memo: temporary authority that never leaves.

The air is thick with grill smoke and policy nonsense. One minute the bureaucrats are telling you research overhead is a problem, the next minute the paperwork doors slam shut and they disappear into the night. That is the smell of a scheme cooling off. And I am not buying it.

White House won’t appeal the NIH indirect cost ruling to the Supreme Court

Here is what got dropped on the courthouse barbecue. The NIH had been pushing a flat 15% cap on reimbursements for indirect research costs. Indirect costs are the unglamorous but essential stuff that keeps the lights on and the experiments running, including shared lab infrastructure and other operational expenses that grants rarely cover directly. The historical range for indirect cost rates is typically around 27% to 28%. NIH estimated the cap could save more than $4 billion annually. Universities and academic medical centers warned it would punch the nation’s research engine in the gut, not just trim fat. Then the courts put a brake on it.

The villain wanted the lab money, and they called it efficiency

I have heard this song before, the AM-radio hymn of the administrivia class. They stand at the grill and point at smoke like it is the enemy. They promise that cutting overhead will magically turn every dollar into pure science. But indirect costs are what pay for the systems that let scientists do science. You cannot run a lab on vibes. You run it on facilities, compliance, and infrastructure.

And let’s be honest about incentives. When someone talks about saving billions by shrinking reimbursement for what keeps research standing, what they are really reaching for is control. Control of budgets, control of staffing, control of who survives long enough to do the next trial. That is not integrity. That is budget domination cosplay.

After the appeals court block, the Supreme Court fight never got finished

After an early January 2026 appeals court decision upheld the block on the cap, federal law gave the parties a window to petition the Supreme Court. Reporting says parties had 90 days to petition, and the Trump administration did not submit the required paperwork by the April 6 deadline. The result: the legal challenge effectively ends, and the earlier ruling stands.

That is not heroic restraint. That is a retreat. The villain does not win by proving the policy is right. The villain wins, when they can, by trying to force a system to accept their preferred accounting. This time, the system said no, and the administration picked the safest path out the side door.

What this means next

The institutions that rely on negotiated indirect cost rates argued the cap would undermine research capacity, threaten staffing security, and stall scientific progress, including access to clinical trials and treatments. With the Supreme Court appeal not pursued, those fears do not get instantly amplified by an abrupt rate shift. Research is a long-haul engine. Stability is the unsexy hero of American innovation.

Some research associations have pushed for alternative approaches, including a more transparent Financial Accountability in Research, or FAIR, model, aimed at addressing overhead concerns without a blunt instrument rate cut. If you want fixes people can actually audit, show the buckets and let oversight do its job.

So here is the question: if the administration did not have the paperwork chops to finish the Supreme Court fight on NIH indirect costs, why should anyone trust them with the next round of science funding games?

The newsroom coffee tastes like burnt pennies and old subpoenas. The scanner is hissing. Somewhere in a committee hearing room, a microphone is waiting for another person in a suit to say “efficiency” like it is a moral virtue instead of a budget axe.

Now to the part they hoped would sound like paperwork: the Trump administration abandoned its Supreme Court challenge tied to the National Institutes of Health (NIH) move to cap so-called “indirect costs” on research grants.

What happened (and what the courts did)

NIH, under the administration, pushed a flat 15% cap on facilities and administrative costs. That bland label covers the unsexy infrastructure that keeps research standing: labs, compliance, safety systems, staff, and the building overhead that makes discovery possible.

Courts blocked the cap. The First Circuit upheld that block in early January 2026. And on April 9, 2026, the administration walked away from its Supreme Court challenge.

Congress, meanwhile, has included language in spending bills aimed at preventing agencies from changing how universities are reimbursed for these costs for a defined period, plus added reporting requirements.

So yes: this route to a cap is not happening right now.

Do not clap like the fire is out because the arsonist stepped away from one match.

Translation: “Indirect costs” is the scapegoat

Translation: when they say “indirect costs,” they want you picturing plush offices and lazy administrators.

What they do not want you picturing is the real list: biosafety compliance, grants management and audit trails, secure data systems, animal care, human-subject protections, and the literal building holding the freezers holding the samples holding the future.

The cap was sold as reform. Mechanically, it would have shifted costs off the federal government and onto universities, states, hospitals, and ultimately patients and workers. Or it would have forced cuts: layoffs, shuttered projects, fewer grants, slower progress.

The First Circuit decision described the cap as conflicting with congressional appropriations language directing NIH to keep reimbursing based on negotiated rates, not a one-size-fits-all ceiling.

Here is the mechanism: make research brittle, then blame it

Here is the mechanism: you do not have to ban research to sabotage it. You just slash the boring parts. You make labs brittle. You force scientists into more begging and less building. Then, when projects slow and institutions stumble, you point at the wreckage and call public science “inefficient.”

Starve, stumble, sneer, privatize.

Follow the money: who benefits when public science gets squeezed

Follow the money: weakening NIH-funded capacity does not erase demand for innovation. It reroutes it. Private capital loves a bottleneck. When public research slows, the monopoly story gets easier: fewer publicly supported discoveries, more proprietary platforms, more paywalls, more “partnerships” that look like charity until you audit the IP terms.

The quiet part: a country that cannot sustain public research becomes a nation of press releases and punditry. PR fog over lab results.

Mic drop: audit the saboteurs, not the labs

Abandoning the Supreme Court challenge is a retreat, and it matters. It also proves court pressure and congressional guardrails can work.

Now do the next step: drag this episode into sunlight. Oversight hearings. Internal memos. Lobbyist meetings. Cost models. Then tighten the guardrails so the same sabotage does not return under a new memo number.

I was tucked into a quiet library corner with a dog-eared civics book, the kind that smells like dust, paste, and old arguments, when my phone served up the modern town crier: a countdown to a capsule reentering at the wrong end of 24,000 miles an hour. Same republic, different pamphlets.

NASA says Artemis II is scheduled to splash down off San Diego tonight. Orion will hit a communications blackout on the way down, then shed hardware and deploy parachutes in stages: drogue chutes around 22,000 feet, main parachutes around 6,000 feet. After that, the Pacific does what it does best: it waits.

What NASA says will happen tonight

The agency has been unusually plainspoken about the mechanics. On Thursday, NASA laid out final reentry preparations for Orion and a targeted splashdown time of about 8:07 p.m. Eastern (5:07 p.m. Pacific) off the California coast. The sequence, by NASA’s own description, turns a spacecraft into a very expensive sea bobber via blackout, jettisons, and staged chute deployment.

This is the first crewed lunar flyby since the Apollo era, ending with a question that is both technical and civic: did the system work when it mattered most?

The people inside the capsule are not props

The crew has names, families, and a constitutional right not to be treated like set dressing: commander Reid Wiseman, pilot Victor Glover, mission specialist Christina Koch, and Canadian Space Agency astronaut Jeremy Hansen. The Associated Press reported they spent their last full day in space tidying up, bracing for the return fireball, and reflecting on the surreal fact that humans are again doing the thing we used to do before disco died the first time.

The tradeoff: Big projects, big excuses

Yes, it is awe-inspiring. It is also policy. And policy is where romance tends to get mugged in the parking lot.

• Spending and power: Artemis is public science and engineering, but it lives in Washington’s ecosystem of contractors, timelines, and narrative management. When splashdown is the headline, procurement details hide behind the flag.
• Sunlight matters: I am not allergic to spending on real capabilities. I am allergic to spending that cannot survive sunlight.

The Paine test

Does this expand liberty or concentrate power? A healthy space program can expand liberty in the long run. But concentrated power sneaks in when national prestige becomes a blank check and the public is treated like an audience, not an owner. Owners get receipts.

The Orwell check

Space policy arrives wrapped in competition language, especially with China. Some of that is real. Some is convenient. The Guardian, citing NASA leaders, emphasized the extreme velocities involved in Orion’s return. That technical truth can be repackaged into a political moral lecture: unity, urgency, and please stop asking questions. If “we cannot afford delays” starts meaning “we cannot afford oversight,” the mission has already taken on water.

Guardrails that should land with the capsule

If Orion splashes down safely tonight, the civic job starts tomorrow morning, when the cameras move on and the appropriations tables reappear. Congress should fund what works, fix what does not, and demand plain answers on cost, schedule, and safety margins. Inspectors general should stay boring and relentless. NASA should keep publishing operational clarity, not just victory laps. And the White House, regardless of party, should resist turning scientific achievement into a permission slip for unrelated power grabs.

We can celebrate Artemis II without surrendering our skepticism. That is not cynicism. That is citizenship.

The newsroom air feels like hickory smoke trapped in a printer, and the latest wave of health claims coming off the internet looks like the same old charcoal-burnt nonsense dressed up in new AI cologne. If you smell it, it is because editors from 20 medical and health journals just told the country, out loud, that the quality of health information is getting cooked on an open flame.

20-journal editors call for stronger safeguards for health and medical science information

According to a joint editorial released for publication starting April 9, 2026, editors warn that misleading health information is spreading faster, alongside political pressure and the rapid spread of digital tools, including artificial intelligence. Lead author Dr. Scott C. Ratzan frames the problem as not just sloppy communication, but a steady erosion of trust in the scientific method and the scientific record.

Here is the part that raises the smoke alarm. These editors are not asking for the moon. They are asking for guardrails. They want oversight for how digital platforms and AI systems handle health and medical claims, and they remind everyone that the mission of journals is to evaluate information through rigorous, peer-reviewed scientific inquiry.

When misinformation wins, the grifters and power-hunters grab the meat

Name the villains like you name the grease fire that starts behind the grill. One villain is the political theater crowd that wants science to be a checkbox, not a method. The editorial points to political attacks on science and a decline in support for research and scientific literacy.

The other villain is the algorithm crowd, the platform middlemen, and the AI-content factories that profit when nobody checks the receipts. If AI can generate plausible medical narratives at scale, the temptation is obvious: publish first, fact-check later, or never. The editorial emphasizes that AI can accelerate and distort transmission of information unless governance and oversight keep it honest.

Guardrails do not kill freedom, they protect it from fraud

Protecting quality and integrity of health information is accountability, not censorship. The editorial argues that digital platforms and AI systems have a public duty to help protect accuracy and reliability, especially when content is based on what scientists and journal authors have published.

And remember the calendar detail: EurekAlert notes that the editorial will be available in the publishing period between April 9 and June 30, 2026. It also points to a future push toward recommendations, with a Nature Medicine commission on Quality Health Information for All expected to issue specific recommendations in 2027.

What this means for America

If you are a patient, this editorial is a warning label on the internet highway. If you are a policymaker, it is a clue that leaving health information governance to whoever screams the loudest is a recipe for more confusion, not less.

America does not need more hot takes about medicine. We need better plumbing for truth, the kind that keeps the bloodstream of policy and public understanding clean.

The newsroom is lit like an interrogation room. Stale coffee, hot printer paper, the hiss of a scanner that never sleeps. On my desk: the FY27 President’s Budget Request, dressed up like a glossy brochure and built like a threat model.

This is not “just numbers.” It is a rehearsal for what kind of government they want to run.

What the FY27 request targets: NSF, NASA science, NIH

The White House dropped its Fiscal Year 2027 budget request on April 3, 2026. Read it straight and it looks like a demolition permit for public science: a major cut to the National Science Foundation, a near-halving of NASA’s Science Mission Directorate, and another cut to the National Institutes of Health.

The American Astronomical Society summarized the headline numbers: about a 55% cut to NSF, a 47% cut to NASA science, and a 13% cut to DOE’s Office of Science.

Meanwhile, AP reported a $1.5 trillion defense spending request. Domestic spending gets treated like loose change in a couch. Defense gets treated like gravity.

And NIH? Axios reported the FY27 request proposes a $5 billion cut and revives the idea of capping NIH indirect costs at 15%.

Yes, Congress writes the final checks. No, that does not make this harmless. It’s still a signal flare to agencies, universities, labs, hospitals, and the whole research workforce: prepare to shrink.

Translation: “Indirect costs” means “starve the plumbing, then blame the leak”

Translation: “Indirect costs” are the boring systems that keep research legal and safe: compliance, cybersecurity, accounting, facilities, animal care, waste disposal. Cap that at 15% across the board and you are not cutting “waste.” You are cutting the capacity to do the work without fraud, infections, or lawsuits.

When the faucet tightens, the first casualties are not executive salaries. It’s lab techs, grad students, clinical coordinators, and postdocs.

Follow the money: austerity for science, a blank check for the war machine

Follow the money: This isn’t “reducing spending.” It’s reallocating power. Defense procurement is politically protected, spread across districts, and padded with contractors behind boardroom glass. Public science is decentralized and inconvenient. It produces facts about climate, pollution, workplace exposure, pricing, and regulatory failure. You cannot easily monopolize it or message-control it.

NASA science shows the split: Space.com reported the proposal would cut NASA’s Science Mission Directorate from about $7.25 billion to $3.9 billion. The camera-friendly stuff keeps its shine. The measurement work gets shoved toward the shredder.

The quiet incentive is simple. Exploration sells. Measurement tattles.

Here is the mechanism: make science precarious, then call it broken

Here is the mechanism: propose massive cuts and cost caps, trigger freezes and delays, and bleed talent even if Congress later blocks the worst of it. Then push institutions into “partnerships” and “philanthropy.” Translation: dependency on donors, corporate sponsors, and venture logic. Finally, point at the weakened public system and label it inefficient. Privatization by stealth strolls in wearing a contractor badge.

The quiet part: the target is not just budgets. It’s independence. A federal science enterprise with enough money to say “no” is hard to bully. A thin, anxious version is easy to redirect or replace.

Science is not perfect. Institutions have real problems. But you do not fix integrity by detonating capacity. You fix it with transparency, oversight, and enforcement.

I read federal budgets the way some people read horoscopes: not because I think the universe is whispering secrets, but because the pattern tells you who is about to get pushed off the porch. The paper is always clean. The language is always hygienic. The consequences, as usual, belong to someone else.

This week’s scent is antiseptic with a sharp undertone of power.

What the proposed NIH budget does (in plain English)

Reporting Tuesday night says senior lawmakers, research groups, and patient advocates are bristling at President Trump’s request to cut the National Institutes of Health by about $5 billion, with Senate Appropriations Chair Susan Collins calling the proposed biomedical research cuts unwarranted. That is not a backbench gripe. That is a committee-room chair tapping a folder with a pen.

The administration’s FY 2027 HHS Budget in Brief proposes $41.2 billion in discretionary budget authority for NIH, described as $3.5 billion below FY 2026. It also shows total NIH program level falling from $46.271 billion in FY 2026 to $41.471 billion in FY 2027, a $4.8 billion drop.

Then comes the part that makes university finance offices reach for a paper bag: the budget says it will continue a policy capping indirect cost rates at 15 percent. Translation: Washington wants to dictate how much of a grant can fund the unglamorous necessities that keep the glamorous science alive.

The budget also proposes eliminating NIH components including the Fogarty International Center, the National Center for Complementary and Integrative Health, and the National Institute on Minority Health and Health Disparities. It points readers to the CDC chapter for the National Institute of Environmental Health Sciences, reflecting a proposed shift out of NIH.

The Orwell check: when “restoring trust” turns into a lever

The budget wraps itself in good words: trust, transparency, accountability, reproducibility. Fine. I would gladly embroider them on a civics textbook.

But the Orwell check is about what the words are doing. Here, “trust” reads like a hall pass for tighter central control: structural eliminations, reorganizations, and a hard cap on indirect costs, alongside promises to fully fund research project grants upfront and cap certain salary authorities. That is not just budgeting. That is governance by spreadsheet.

The liberty ledger and the tradeoff

• Taxpayers: A legitimate interest in waste reduction and rigorous science.
• Researchers and the public: A freedom interest in inquiry that is not pre-approved by politics.

A blanket 15 percent cap sounds like a clean haircut until you remember lab science lives in buildings, secure networks, data storage, regulated environments, and compliance. If Washington sets an arbitrary ceiling from 30,000 feet, universities either subsidize federal research with tuition and philanthropy, do less of it, or shift it to places that can eat the costs.

Yes, the budget highlights biosafety and biosecurity, and it puts money toward replication and reproducibility, including $100 million to elevate those efforts across NIH. It also points to data-sharing frameworks described as privacy-preserving and scalable, and to real-world data infrastructure. Not cartoon-villain goals.

But ASBMB warned this week that the community is still reeling from disruptions and delays, noting that even after Congress rejected last year’s proposed cuts, the ultimately appropriated FY 2026 funding took nearly two months to reach NIH, delaying awards. Jittery funding makes labs cautious and ambition expensive.

The Paine test

Oversight that demands rigorous, reproducible, secure science can expand liberty. But using budgets to corner and reorganize the research ecosystem concentrates power, and once that tool becomes furniture, the next administration will not throw it out.

So here’s the practical path: force clarity in hearings about what the 15 percent cap would break, what it would save, and who pays the shifted costs. Put inspectors general and GAO on indirect-cost audits and publish comparisons people can actually read. Require plain-language rationales and independent review for eliminations or relocations, with a real comment period. And keep courts available when statutory requirements or arbitrary agency action are in play.

One last question for the comment section: if Washington truly wants to “restore trust,” why does it keep reaching first for the axe instead of the audit?

The grill is still cracklin’, the AM radio is hissing, and then I hear it. Another week, another lab check, another taxpayer dollar rollin’ into a settlement instead of a scientific breakthrough.

DOJ: $152,500 to resolve NSF SBIR and PPP expense-claim allegations

According to a U.S. Department of Justice announcement from the Eastern District of North Carolina, Dr. Michael Harrington and Genoverde Bioscience, Inc. agreed to pay $152,500 to resolve allegations tied to National Science Foundation grant payments and Payment Protection Program loans.

The DOJ describes the case as involving allegedly false and duplicative expense claims under government grants. It also says the matter included allegedly improper efforts connected to PPP loans and PPP loan forgiveness. This was handled through a civil settlement, and the announcement stresses there was no judicial determination and no admission of liability.

What was alleged? Paperwork games with public funding

In the government’s framing, the grants involved research expenses including work described as harvesting industrial hemp and trees. The DOJ announcement characterizes the dispute as allegations, resolved by settlement, not a court finding.

Now, I know science folks love process. But when paperwork games start smellin’ like a slick used-car lot, the only review that matters is the one where the government checks the books and pulls the pen from the grifter’s hand.

Integrity and accountability, with the lab money guard on duty

The announcement also points to integrity for the SBIR grant program and accountability for false claims and misrepresentation schemes. Translation for folks in the back row: somebody is supposed to guard the lab money, and the system responded.

America’s takeaway: protect the pipeline, or the whole ecosystem pays

This settlement might look small next to big research budgets, but the price is confidence. When public money is treated like a piggy bank, oversight tightens, paperwork grows, and honest teams get forced to carry extra skepticism.

A local report shared by WRAL describes the same core event: the settlement resolving allegations involving NSF grants and PPP loans, with DOJ referencing the role of NSF oversight and the inspector general.

Here’s the freedom-sermon punchline: if public money is the fuel for American ingenuity, fraud is a match in the glove box. It doesn’t just burn one car. It threatens the whole convoy.

The newsroom coffee tastes like burned plastic. Committee-room déjà vu. My phone vibrates with budget push alerts while the police scanner coughs static. Outside, the city glows that sickly neon that shows up when power is being moved around quietly, like furniture after a crime scene.

Here’s the furniture shift: the Trump administration’s fiscal year 2027 budget blueprint takes another swing at public science. The National Science Foundation is pegged at roughly $4 billion, a huge drop from FY2026 levels. The National Institutes of Health is targeted around $41.3 billion, plus a grab bag of eliminations and consolidations that reads like a demolition plan written in a lobbyist hallway.

The numbers: NSF about $4B, NIH about $41.3B

Chemical & Engineering News lays it out: NSF down to about $4 billion, described as a 54.5% cut from FY2026, with deep reductions across major directorates. NIH is next, pegged at roughly $41.3 billion, about a 10.5% drop, alongside proposals to eliminate or zero out specific institutes and centers, including units focused on minority health and international work.

Axios adds the political framing: the budget text paints NIH as a villain and revives the proposal to cap NIH indirect costs at 15%.

Translation: “alignment” is a loyalty filter, “indirect costs” is the lab’s circulatory system

Translation: when a budget page boasts about “strategic alignment” while promising to eliminate “woke and weaponized” grant programs, it is doing politics with a calculator. It signals that work stays fundable if it fits the administration’s culture-war fixations.

And “indirect costs” are not a junk drawer. They cover the dull, necessary infrastructure that keeps science real: compliance, facilities, secure systems, maintenance, staff. Cap that at 15% and you are not trimming fat. You are smashing the plumbing and calling it efficiency.

Here is the mechanism: starving a public system does not end the need. It changes who gets paid to meet it.

Follow the money: less public science, more private gatekeeping

Cut NSF and NIH and the demand for research does not evaporate. It migrates into private capital, defense contracting, and corporate partnerships with nondisclosure agreements, IP grabs, and results filtered through PR. Research still happens, just behind boardroom glass instead of peer review.

AP’s reporting on the budget’s overall shape notes the administration pushing for $1.5 trillion in defense spending while domestic programs take the haircut. Translation: there is always money for war theater, and always austerity for the lab that might prevent the next mass disability event.

The quiet part: control, not efficiency

The loud part is “waste,” “overhead,” and culture-war sludge. The quiet part is power. Science acts like a public referee: it tells you when air is toxic, when drugs are dangerous, when heat is rising, when institutions are lying. That threatens people who profit from denial.

C&EN also flags concerns about spending and commitment patterns, including worries NIH has been committing less than expected in the current fiscal year. That is austerity as a self-fulfilling audit finding: under-spend, then cite the under-spend to justify the next cut.

This lands on campuses as layoffs, lab closures, and early-career researchers getting crushed first. It lands on the public as less leverage: public funding can demand transparency; private funding offers press releases and proprietary dashboards.

My mic-drop ask: Congress should subpoena the assumptions behind these cuts, inspect agency spending patterns for deliberate under-commitment, and audit the lobbying that blooms right before public science gets strangled. Universities should stop acting like polite grant-seekers and start acting like employers defending their workforce. And the rest of us should treat science funding like a labor issue, a disability issue, a climate survival issue, because it is.